To assess the efficacy, safety and tolerability of vonoprazan, a novelpotassium-competitive acid blocker, as a component of Helicobacter pylori eradication therapy.

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100044683

Enrollment

Unknown

Registered

2021-03-25

Start date

2021-04-01

Completion date

Unknown

Last updated

2021-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection of Helicobacter pylori

Interventions

triple therapy group:VPZ 20 mg bid, amoxicillin 1000 mg bid and clarithromycin 500 mg bid for 2 week

quadruple?therapy group:Esomeprazole 20?mg?as?part?of?first-line?quadruple?therapy

Eligibility

Sex/Gender

All

Age

20 Years to No maximum

Inclusion criteria

Inclusion criteria: Male or female H pylori-positive patients aged >= 20 years with gastric or duodenal ulcer history.

Exclusion criteria

Exclusion criteria: The main exclusion criteria included acute upper GI bleeding, active gastric or duodenal ulcers, acute gastric or duodenal mucosal lesions, previous H pylori eradication therapy, surgery which might affect gastric acid secretion (upper GI resection or vagotomy), Zollinger–Ellison syndrome or other gastric acid hypersecretion disorders, serious neurological, cardiovascular, pulmonary, hepatic, renal, metabolic, GI,urological, endocrinological or haematological disorders, need for surgery, history of drug (including alcohol) abuse, history of malignancy and female subjects who were pregnant or lactating.

Design outcomes

Primary

Measure	Time frame
13C-urea breath tests;	—

Countries

China

Contacts

Public ContactFan Li

The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University

158551814@qq.com+86 13815000812

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026